Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective "Real Life" analysis of activity and safety

被引：1
|
作者：
Fabbri, M. A. [1 ]
Cortesi, E. [2 ]
Marchetti, P. [3 ]
Santini, D. [4 ]
Gamucci, T. [5 ]
Angelini, F. [6 ]
Longo, F. [7 ]
Milano, A. [3 ]
Mancini, M. L. [2 ]
Giuli, A. [7 ]
Quadrini, S. [5 ]
Sperduti, I. [8 ]
Pellegrino, A. [9 ]
Ratta, R. [4 ]
Primi, F. [1 ]
Chilelli, M. G. [1 ]
Ruggeri, E. M. [1 ]
机构：
[1] Osped Belcolle, UOC Oncol, Viterbo, Italy
[2] Policlin Umberto 1, UOC Oncol B, Rome, Italy
[3] Osped SantAndrea, UOC Oncol, Rome, Italy
[4] Campus Biomed, UOC Oncol, Rome, Italy
[5] Osped SS Trinita, UOC Oncol, Sora, Italy
[6] Regina Apostolorum, UOC Oncol, Albano Laziale, Italy
[7] Policlin Umberto 1, UOC Oncol A, Rome, Italy
[8] Ist Regina Elena, Biostat Unit, I-00161 Rome, Italy
[9] San PIetro FBF, UOC Oncol, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31363-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2544
引用
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [21] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
  • [22] Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation
    Prati, Veronica
    Ruatta, Fiorella
    Aversa, Caterina
    Gernone, Angela
    Galizia, Danilo
    Bonzano, Alessandro
    Torino, Sofia
    Nuzzolese, Imperia
    Marandino, Laura
    Aglietta, Massimo
    Ortega, Cinzia
    FUTURE ONCOLOGY, 2018, 14 (05) : 443 - 448
  • [23] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    Koninckx, M.
    Marco, J. L.
    Perez, I.
    Faus, M. T.
    Alcolea, V.
    Gomez, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03) : 314 - 323
  • [24] Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
    Sigorski, Dawid
    Wilk, Michal
    Gawlik-Urban, Angelika
    Salek-Zan, Agata
    Kiszka, Joanna
    Malik, Mateusz
    Czerko, Katarzyna
    Kuc, Kamil
    Szczylik, Cezary
    Kubiatowski, Tomasz
    Cybulska-Stopa, Bozena
    Filipczyk-Cisarz, Emilia
    Bodnar, Lubomir
    Skoneczna, Iwona
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [26] The economics of abiraterone acetate for castration-resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 175 - 179
  • [27] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Salem, Mohamed
    Garcia, Jorge A.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 92 - 96
  • [28] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Mohamed Salem
    Jorge A. Garcia
    Current Oncology Reports, 2011, 13 : 92 - 96
  • [29] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Lily P. H. Yang
    Katherine A. Lyseng-Williamson
    Drugs & Aging, 2012, 29 : 243 - 248
  • [30] New drugs in the treatment of metastatic castration-resistant prostate cancer: abiraterone acetate
    Martinez-Hernandez, Lucia
    Martinez-Prieto, Marcela
    Galvan-Salazar, Gabriel
    GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (01): : 32 - 40
12345